Scholarlink

<p>Here we analysed recently released treatment data from the US President’s Emergency Plan for AIDS Relief (PEPFAR) programme following a year of disruption. Globally (<i>n</i> = 55 countries), the programme reported approximately 1.97 million (−10.2%) fewer individuals receiving PEPFAR-supported antiretroviral treatment in fiscal year (FY) 2025 as compared with FY2024. FY2025 treatment budget execution declined by approximately 8 percentage points compared with the historical mean. Within a subset of countries selected for further analysis (<i>n</i> = 26), most experienced absolute declines in PEPFAR-supported treatment and 14 deviated negatively from pre-2025 trends. For South Africa, PEPFAR reported a decline of ∼1.73 million individuals on direct PEPFAR-supported treatment and an increase of ∼1.64 million individuals on treatment benefitting solely from the programme’s broader support to health systems, yielding a net treatment loss of 94,881 (−1.8%) individuals. Outstanding questions remain regarding the drivers, persistence and broader impact of PEPFAR-supported treatment shifts, underscoring the need for timely programme data.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Shifts in PEPFAR-supported HIV treatment in 26 countries from 2024 to 2025

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Ramona Godbole,
  • Jonas Wachinger,
  • Catherine Nichols,
  • Marissa Courey,
  • Till Bärnighausen,
  • Rose Mpembeni,
  • Frank Tanser,
  • Shannon A. McMahon

摘要

Here we analysed recently released treatment data from the US President’s Emergency Plan for AIDS Relief (PEPFAR) programme following a year of disruption. Globally (n = 55 countries), the programme reported approximately 1.97 million (−10.2%) fewer individuals receiving PEPFAR-supported antiretroviral treatment in fiscal year (FY) 2025 as compared with FY2024. FY2025 treatment budget execution declined by approximately 8 percentage points compared with the historical mean. Within a subset of countries selected for further analysis (n = 26), most experienced absolute declines in PEPFAR-supported treatment and 14 deviated negatively from pre-2025 trends. For South Africa, PEPFAR reported a decline of ∼1.73 million individuals on direct PEPFAR-supported treatment and an increase of ∼1.64 million individuals on treatment benefitting solely from the programme’s broader support to health systems, yielding a net treatment loss of 94,881 (−1.8%) individuals. Outstanding questions remain regarding the drivers, persistence and broader impact of PEPFAR-supported treatment shifts, underscoring the need for timely programme data.